title: Functional interaction between beta 2-adrenoceptor agonists and interleukin-4 in the regulation of CD23 expression and release and IgE production in human.
abstract: Normal human peripheral blood mononuclear cells (PBMC) produced IgE when stimulated with IL-4. In the present report it was shown that beta 2-adrenoceptor agonists, salbutamol and fenoterol, potentiated the IL-4-induced IgE production without significantly affecting the expression of the low affinity receptor for IgE at the cell surface of monocytes and B lymphocytes. However, beta 2-adrenoceptor agonists were shown to enhance at day 7 the IL-4-induced release of the soluble form of CD23 (sCD23) by PBMC. This effect was specific since a beta-adrenoceptor antagonist, D,L-propranolol, inhibited the IL-4-induced IgE production by these cells. Alternatively, the beta 2-adrenoceptor agonists inhibited the production by these cells of interferon-gamma (IFN-gamma) but did not affect the production of IL-4 when stimulated with phytohemagglutinin A + a phorbol ester. These data suggest that beta 2-adrenoceptor agonists influence the IL-4-induced IgE production in humans by enhancing the release of sCD23 and inhibiting the production of endogenous IFN-gamma. In addition to the effect on the IL-4-induced IgE production it was shown that beta 2-adrenoceptor agonists potentiated the effect of IL-4 on a human promonocytic cell line, U 937, by enhancing CD23 expression and release and by inducing the differentiation of these cells into monocyte-like cells. Taken together, these data indicate that beta 2-adrenoceptor agonists potentiated the effect of IL-4 and that this functional interaction is different considering the cell-lineage and the stage of differentiation of these cells.
authors.affiliation: INSERM U196, Institut Curie, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Paul-Eugene
authors.forename: J P
authors.initials: JP
authors.lastname: Kolb
authors.forename: A
authors.initials: A
authors.lastname: Calenda
authors.forename: J
authors.initials: J
authors.lastname: Gordon
authors.forename: H
authors.initials: H
authors.lastname: Kikutani
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: J M
authors.initials: JM
authors.lastname: Mencia-Huerta
authors.forename: P
authors.initials: P
authors.lastname: Braquet
authors.forename: B
authors.initials: B
authors.lastname: Dugas
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000494:pharmacology; D002454:Cell Differentiation; D002460:Cell Line / Q000187:drug effects; D005280:Fenoterol / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis* / Q000276:immunology; D007371:Interferon-gamma / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects; D017455:Receptors, IgE / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D000318:Adrenergic beta-Agonists; D017455:Receptors, IgE; D011994:Recombinant Proteins; D005280:Fenoterol; D007073:Immunoglobulin E; D007371:Interferon-gamma; D000420:Albuterol